Efficacy of flavonoids in the management of high blood pressure

Nutrition Reviews

Volumn 73, Issue 12, 2015, Pages 799-822

  Clark, Jaime L ^a,b   Zahradka, Peter ^a,b   Taylor, Carla G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b The Inst of Cardiovascular Sciences   (Canada)

Author keywords

Blood pressure; Endothelial function; Flavonoids; Hypertension

Indexed keywords

ACETYLCHOLINE; ANTHOCYANIN; ANTIHYPERTENSIVE AGENT; FLAVAN 3 OLS; FLAVANOL DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL FUNCTION; CARDIOVASCULAR SYSTEM EXAMINATION; DIET THERAPY; DRUG EFFICACY; ENDOTHELIUM; FLOW-MEDIATED DILATION TEST; HUMAN; HYPERTENSION; LASER DOPPLER FLOWMETRY; MYOGRAPHY; NONHUMAN; THORACIC AORTA; THORACIC AORTIC RING ASSAY; WIRE MYOGRAPHY; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; FLAVONOIDS; HUMANS; HYPERTENSION;

EID: 84973450029     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuv048     Document Type: Article

References (151)

1. World Health Organization. Cardiovascular disease. WHO website. http://www.who.int/cardiovascular_diseases/en. Accessed August 13, 2015.
2. Diao D, Wright JM, Cunduff DK, et al. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8:CD006742. doi:10.1002/14651858. CD006742.pub2.
3. Briet M, Schiffrin EL. Treatment of arterial remodeling in essential hypertension. Curr Hypertens Rep. 2013;15:3-9.
4. Borde P, Mohan M, Kasture S. Effect of myricetin on deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Nat Prod Res. 2011;25:1549-1559.
5. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101:329-335.
6. Beevers G, Lip GY, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ. 2001;322:912-916.
7. Rahimmanesh I, Shahrezaei M, Rashid B. High blood pressure and endothelial dysfunction: effects of high blood pressure medications on endothelial dysfunction and new treatments. J Res Med Sci. 2012;2:S298-S311.
8. Lee QY, Redmond SJ, Chan GS, et al. Estimation of cardiac output and systemic vascular resistance using a multivariate regression model with features selected from the finger photoplethysmogram and routine cardiovascular measurements. Biomed Eng Online. 2013;12:19. doi:10.1186/1475-925X-12-19.
9. Kurtel H, Rodrigues SF, Yilmaz CE, et al. Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia. J Am Soc Hypertens. 2013;7:14-23.
10. Feng M, Whitesall S, Zhang Y, et al. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens. 2008;21:1288-1291.
11. Kurtz TW, Griffin KA, Bidani AK, et al. Recommendations for blood pressure measurement in animals: summary of an AHA scientific statement from the Council on High Blood Pressure Research, Professional and Public Education Subcommittee. Arterioscler Thromb Vasc Biol. 2005;25:478-479.
12. Pauline M, Avadhany ST, Maruthy KN. Non invasive measurements of systolic blood pressure in rats: a simple technique. Al Ameen J Med Sci. 2011;4:365-369.
13. Plehm R, Barbosa ME, Bader M. Animal models for hypertension/blood pressure recording. In: Q Wang, ed. Cardiovascular Disease: Methods and Protocols, Vol. 2. Totowa, NJ: Humana Press; 2006.
14. Erken HA, Erken G, Genç O. Blood pressure measurement in freely moving rats by the tail cuff method. Clin Exp Hypertens. 2013;35:11-15.
15. Huetteman DA, Bogie H. Direct blood pressure monitoring in laboratory rodents via implantable radio telemetry. In: K Di Petrillo, ed. Cardiovascular Genomics Methods and Protocols. New York, NY: Humana Press; 2009:57-60.
16. Kubota Y, Umegaki K, Kagota S, et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Bio Pharm Bull. 2006;29:1756-1758.
17. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716.
18. Berger A. Oscillatory blood pressure monitoring devices. BMJ. 2001;323:919. doi:http://dx.doi.org/10.1136/bmj.323.7318.919.
19. Ostchega Y, Zhang G, Sorlie P, et al. Blood pressure randomized methodology study comparing automatic oscillometric and mercury sphygmomanometer devices: National Health and Nutrition Examination Survey, 2009-2010. http://www.cdc.gov/nchs/data/nhsr/nhsr059.pdf. Published October 5, 2012. Accessed August 13, 2015.
20. Ward M, Langton JA. Blood pressure measurement. Contin Educ Anaesth Crit Care Pain. 2007;7:122-126. doi:10.1093/bjaceaccp/mkm022.
21. Kaczorowski J, Dawes M, Gelfer M. Measurement of blood pressure: new developments and challenges. B C Med J. 2012;54:399-403.
22. O'Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ. 2000;320:1128-1134.
23. Warren RE, Marshall T, Padfield PL, et al. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract. 2010;60:675-680.
24. Cua CL, Thomas K, Zurakowski D, et al. A comparison of the Vasotrac with invasive arterial blood pressure monitoring in children after pediatric cardiac surgery. Anesth Analg. 2005;100:1289-1294.
25. Félétou M. The Endothelium. Part 2: EDHF-Mediated Responses: “The Classical Pathway”. San Rafael, CA: Morgan & Claypool Life Sciences Publisher; 2011.
26. Ikemura M, Sasaki Y, Giddings JC, et al. Preventive effects of hesperidin, glucosyl hesperidin and naringin on hypertension and cerebral thrombosis in stroke-prone spontaneously hypertensive rats. Phytother Res. 2012;26:1272-1277.
27. Fernández Vallinas S, Lopez Carreras N, Miguel M, et al. Nitric oxide mediates the antihypertensive and vascular relaxing effects of a soluble cocoa fiber product in spontaneously hypertensive rats. Nitric Oxide. 2013;29:1-3.
28. Lowry JL, Brovkovych V, Zhang Y, et al. Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium. J Biol Chem. 2013;288:4174-4193.
29. Won KJ, Jung SH, Jung SH, et al. DJ-1/park7 modulates vasorelaxation and blood pressure via epigenetic modification of endothelial nitric oxide synthase. Cardiovasc Res. 2014;101:473-481.
30. Lockette W, McCurdy R, Aronow H, et al. Effect of 8-bromo-cyclic guanosine monophosphate on intracellular pH and calcium in vascular smooth muscle. Hypertension. 1989;13:865-869.
31. Wu CC, Yen MH. Higher level of plasma nitric oxide in spontaneously hypertensive rats. Am J Hypertens. 1999;12:476-482.
32. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36:312-318.
33. Perrault R, Zahradka P. Identification of novel signalling roles and targets for G(a) and G(bc) downstream of the insulin-like growth factor 1 receptor in vascular smooth muscle cells. Biochem J. 2013;450:209-219.
34. Nogueira LdP, Knibel MP, Torres MR, et al. Consumption of high-polyphenol dark chocolate improves endothelial function in individuals with stage 1 hypertension and excess body weight. Int J Hypertens. 2012;2012:147321. doi:10.1155/2012/147321.
35. Silva BR, Pernomian L, Bendhack LM. Contribution of oxidative stress to endothelial dysfunction in hypertension. Front Physiol. 2012;3:441. doi:10.3389/ fphys.2012.00441.
36. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:7-17.
37. Nicosia RF, Zhu WH. Rat aortic ring assay of angiogenesis. In: HG Augustin, ed. Methods in Endothelial Cell Biology. Berlin, Germany: Springer-Verlag; 2004:125-144.
38. 2a contributes to blood pressure increases and endothelial dysfunction under chronic NO inhibition. Arterioscler Thromb Vasc Biol. 2011;31:133-1138.
39. Derrett-Smith EC, Dooley A, Khan K, et al. Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther. 2010;12:R69. doi:10.1186/ar2986.
40. Wu-Wong JR, Noonan W, Nakene M, et al. Vitamin D receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol. 2010;2010:625852. doi:10.1155/2010/625852.
41. Zhao Z, Luo Y, Li G, et al. Thoracic aorta vasoreactivity in rats under exhaustive exercise: Effects of Lycium barbum polysaccharides supplementation. J Int Soc Sports Nutr. 2013;10:47. doi:10.1186/1550-2783-10-47.
42. Pantos CI, Tzilalis V, Giannakakis S, et al. Phenylephrine induced aortic vasoconstriction is attenuated in hyperthyroid rats. Int Angiol. 2001;20:181-186.
43. Lu X, Kassab GS. Assessment of endothelial function of large, medium, and small vessels: a unified myograph. Am J Physiol Heart Circ Physiol. 2011;300:H94-H100.
44. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in sponatenously hypertensive rats and normotensive rats. Circ Res. 1977;41:19-26.
45. Puzserova A, Slezak P, Balis P, et al. Long-term social stress induces nitric oxide-indendent endothelial dysfunction in normotensive rats. Stress. 2013;16:331-339.
46. Galleano M, Bernatova I, Puzserova A, et al. (-)-Epicatechin reduces blood pressure and improves vasorelaxation in spontaneously hypertensive rats by NO-mediated mechanism. IUBMB Life. 2013;65:710-715.
47. Spiers A, Padmanabhan N. A guide to wire myography. In: JP Fennell, AH Baker, eds. Hypertension: Methods and Protocols. Vol. 108. Totowa, NJ: Humana Press; 2005:91-104.
48. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011;93:73-80.
49. Arrebola-Monreno AL, Laclaustra M, Kaski JC. Noninvasive assessment of endothelial function in clinical practice. Rev Esp Cardiol (Engl Ed). 2012;65:80-90.
50. Barac A, Campia U, Panza JA. Methods for evaluating endothelial function in humans. Hypertension. 2007;49:748-760.
51. Celermajer DS. Reliable endothelial function: testing at our fingertips? Circulation. 2008;117:2428-2430.
52. Pons Z, Guerrero L, Margalef M, et al. Effect of low molecular grape seed proanthocyanidins on blood pressure and lipid homeostasis in cafeteria diet-fed rats. J Physiol Biochem. 2014;70:629-637.
53. Wilson DE, Van Vlack T, Schievink BP, et al. Lifestyle factors in hypertension drug research: systematic analysis of articles in a leading Cochrane report. Int J Hypertens. 2014;2014:835716. doi:10.1155/2014/835716.
54. American Heart Association. Prevention & treatment of high blood pressure. AHA website. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Prevention-Treatment-of-High-Blood-Pressure_UCM_002054_Article.jsp. Updated September 3, 2014. Accessed December 17, 2014.
55. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
56. Huang N, Duggan K, Harman J. Lifestyle management of hypertension. Aust Prescr. 2008;31:150-153.
57. Heart and Stroke Foundation of Canada. Getting your blood pressure in check. Heart and Stroke Foundation of Canada website. http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3484023/k.2174/Heart_disease__High_blood_pressure. htm. Updated July 2014. Accessed December 17, 2014.
58. Hypertension Canada. Health behaviour management. Hypertension Canada website. https://www.hypertension.ca/en/professional/chep/therapy/healthbehaviour-management. Accessed December 17, 2014.
59. Khan NA, Hemmelgarn B, Herman RJ, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2009;25:287-298.
60. Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001293. doi:10.1371/journal.pmed.1001293.
61. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296-308.
62. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093.
63. Macready AL, George TW, Chong MF, et al. Flavonoid-rich fruit and vegetables improve microvascular reactivity and inflammatory status in men at risk of cardiovascular disease - FLAVURS: a randomized controlled trial. Am J Clin Nutr. 2014;99:479-489.
64. Boeing H, Bechthold A, Bub A, et al. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr. 2012;51:637-663.
65. Chun OK, Chung SJ, Song WO. Estimated dietary flavonoid intake and major food sources of U.S. adults. J Nutr. 2007;137:1244-1252.
66. Cassidy A, O'Reilly EJ, Kay C, et al. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011;93:338-347.
67. Erdman JW Jr, Balentine D, Arab L, et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr. 2007;137(suppl):718S-737S.
68. Chun OK, Lee SG, Wang Y, et al. Estimated flavonoid intake of the elderly in the United States and around the world. J Nutr Gerontol Geriatr. 2012;31:190-205.
69. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013;2013:162750. doi:10.1155/2013/162750.
70. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutrition. 2002;18:75-81.
71. Hollman PCH. Absorption, bioavailability, and metabolism of flavonoids. Pharm Biol. 2004;42:74-83.
72. Simons AL, Renouf M, Murphy PA, et al. Greater apparent absorption of flavonoids is associated with lesser human fecal flavonoid disappearance rates. J Agric Food Chem. 2010;58:141-147.
73. Thilakarathna SH, Rupasinghe HPV. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013;5:3367-3387.
74. Nijveldt RJ, van Nood E, van Hoorn DE, et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001;74:418-425.
75. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharm Rev. 2008;52:673-751.
76. Tapas AR, Sakarkar DM, Kakde RB. Flavonoids as nutraceuticals: a review. Trop J Pharm Res. 2008;7:1089-1099.
77. Agrawal AD. Pharmacological activities of flavonoids: a review. Int J Pharm Sci Nanotech. 2011;4:1394-1398.
78. Watson RR, Preedy VR, Zibadi S. Polyphenols in Human Health, Disease. Vol. 1. Waltham, MA: Elsevier Science; 2014.
79. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventos RM, et al. Estimation of dietary sources and flavonoid intake in a Spanish adult population (EPIC-Spain). J Am Diet Assoc. 2010;110:390-398.
80. Jennings A, Welch AA, Spector T, et al. Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. J Nutr. 2014;144:202-208.
81. Kay CD, Hooper L, Kroon PA, et al. Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. Mol Nutr Food Res. 2012;56:1605-1616.
82. Christensen KY, Naidu A, Parent ME, et al. The risk of lung cancer related to dietary intake of flavonoids. Nutr Cancer. 2012;64:964-974.
83. Hui C, Qi X, Qianyong Z, et al. Flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. PloS One. 2013;8:e54318. doi:10.1371/journal.pone.0054318.
84. Mursu J, Voutilainen S, Nurmi T, et al. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr. 2008;100:890-895.
85. Guerrero L, Castillo J, Quinones M, et al. Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. PLoS One. 2012;7:e49493. doi:10.1371/journal.pone.0049493.
86. During A, Larondelle Y. The O-methylation of chrysin markedly improves its intestinal anti-inflammatory properties: structure-activity relationships of flavones. Biochem Pharm. 2013;86:1739-1746.
87. Gao X, Cassidy A, Schwarzschild MA, et al. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 2012;78:1138-1145.
88. Prasain JK, Carlson SH, Wyss JM. Flavonoids and age-related disease: risk, benefits and critical windows. Maturitas. 2010;66:163-171.
89. van Dam RM, Naidoo N, Landberg R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr Opin Lipidol. 2013;24:25-33.
90. McCullough ML, Peterson JJ, Patel R, et al. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95:454-464.
91. Wang X, Ouyang YY, Liu J, et al. Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr. 2014;111:1-11.
92. Igarashi K, Honma K, Yoshinari O, et al. Effects of dietary catechins on glucose tolerance, blood pressure and oxidative status in Goto-Kakizaki rats. J Nutr Sci Vitaminol (Tokyo). 2007;53:496-500.
93. El-Bassossy HM, Abo-Warda SM, Fahmy A. Chrysin and luteolin attenuate diabetes-induced impairment in endothelial-dependent relaxation: effect on lipid profile, AGEs and NO generation. Phytother Res. 2013;27:1678-1684.
94. Villar IC, Jimenez R, Galisteo M, et al. Effects of chronic chrysin treatment in spontaneously hypertensive rats. Planta Medica. 2002;68:847-850.
95. Gómez-Guzmán M, Jimenez R, Sanchez M, et al. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothe-lin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med. 2012;52:70-79.
96. Yamamoto M, Suzuki A, Hase T. Short-term effects of glucosyl hesperidin and hesperetin on blood pressure and vascular endothelial function in spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo). 2008;54:95-98.
97. Gasparotto A Jr, Gasparotto FM, Lourenco EL, et al. Antihypertensive effects of isoquercitrin and extracts from Topaeolum majus L.: evidence for the inhibition of angiotensin converting enzyme. J Ethnopharm. 2011;134:363-372.
98. Leeya Y, Mulvany MJ, Queiroz EF, et al. Hypotensive activity of an n-butanol extract and their purified compounds from leaves of Phyllanthus acidus (L.) Skeels in rats. Eur J Pharm. 2010;649:301-313.
99. Lv GY, Zhang YP, Gao JL, et al. Combined antihypertensive effect of luteolin and buddleoside enriched extracts in spontaneously hypertensive rats. J Ethnopharmacol. 2013;150:507-513.
100. Godse S, Mohan M, Kasture V, et al. Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. Pharm Biol. 2010;48:494-498.
101. Alam MA, Kauter K, Brown L. Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients. 2013;5:637-650.
102. Olaleye M, Crown O, Akinmoladun A, et al. Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride-induced hypertensive rats. Hum Exp Toxicol. 2014;33:602-608.
103. Rivera L, Moron R, Sanchez M, et al. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity (Silver Spring). 2008;16:2081-2087.
104. Hassellund SS, Flaa A, Kjeldsen SE, et al. Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study. J Hum Hypertens. 2012;27:100-106.
105. Matsuyama T, Tanaka Y, Kamimaki I, et al. Catechin safely improved higher levels of fatness, blood pressure, and cholesterol in children. Obesity. 2008;16:1338-1348.
106. Edwards RL, Lyon T, Litwin SE, et al. Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007;137:2405-2411.
107. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102:1065-1074.
108. Larson A, Witman MAH, Guo Y, et al. Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiontensin-converting enzyme activity or endothelin-1: nitric oxide. Nutr Res. 2012;32:557-564.
109. Zahedi M, Ghiasvand R, Feizi A, et al. Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial. Int J Prev Med. 2013;4:777-785.
110. Kuo MY, Liao MF, Chen FL, et al. Luteolin attenuates the pulmonary inflammatory response involves abilities of antioxidation and inhibition of MAPK and NFjB pathways in mice with endotoxin-induced acute lung injury. Food Chem Toxicol. 2011;49:2660-2666.
111. Si H, Wyeth RP, Liu D. The flavonoid luteolin induces nitric oxide production and arterial relaxation. Eur J Nutr. 2014;53:269-275.
112. Jiang D, Li D, Wu W. Inhibitory effects and mechanisms of luteolin on proliferation and migration of vascular smooth muscle cells. Nutrients. 2013;5:1648-1659.
113. Wu X, Xu T, Li D, et al. ERK/PP1a/PLB/SERCA2a and JNK pathways are involved in luteolin-mediated protection of rat hearts and cardiomyocytes following ischemia/reperfusion. PloS One. 2013;8:e82957.
114. Friese RS, Mahboubi P, Mahapatra NR, et al. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Am J Hypertens. 2005;18:633-652.
115. Pohanka M. Acetylcholinesterase inhibitors: a patent review (2008 - present). Expert Opin Ther Pat. 2012;22:871-886.
116. Kellogg DL Jr, Zhao JL, Coey U, et al. Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. J Appl Physiol. 2005;98:629-632.
117. Anandhi R, Annadurai T, Anitha TS, et al. Antihypercholesterolemic and antioxi-dative effects of an extract of the oyster mushroom, Pleurotus ostreatus, and its major constituent, chrysin, in triton WR-1339-induced hypercholesterolemic rats. J Physiol Biochem. 2013;69:313-323.
118. Brown E, Hurd NS, McCall S, et al. Evaluation of the anxiolytic effects of chrysin, a passiflora incarnata extract, in the laboratory rat. AANA J. 2007;75:333-337.
119. Wolfman C, Viola H, Paladini A, et al. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharm Biochem Behav. 1994;47:1-4.
120. He XL, Wang YH, Bi MG, et al. Chrysin improves cognitive deficits and brain damage induced by chronic cerebral hypoperfusion in rats. Eur J Pharm. 2012;680:41-48.
121. Levick JR. Overview of the cardiovascular system. In: An Introduction to Cardiovascular Physiology. 5th ed. Boca Raton, FL: CRC Press; 2010.
122. Galindo P, Gonzalez-Manzano S, Zarzuelo MJ, et al. Different cardiovascular protective effects of quercetin administered orally or intraperitoneally in spontaneously hypertensive rats. Food Funct. 2012;3:643-650.
123. Loke WM, Proudfoot JM, Hodgson JM, et al. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2010;30:749-757.
124. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138:211-219.
125. Chen AY, Chen YC. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem. 2013;138:2099-2107.
126. Kim SH, Choi KC. Anti-cancer effect and underlying mechanism(s) of kaempferol, a phytoestrogen, on the regulation of apoptosis in diverse cancer cell models. Toxicol Res. 2013;29:229-234.
127. Duro CC, Ciena AP, De Almeida SR, et al. Qualitative study of young, adult, and aged Wistar rats temporomandibular synovial membrane employing light, scanning, and transmission electron microscopy. Microsc Res Tech. 2012;75:1522-1527.
128. Flamini R, Mattivi F, De Rosso M, et al. Advanced knowledge of three important classes of grape phenolics: anthocyanins, stilbenes and flavonols. Int J Mol Sci. 2013;14:19651-19669.
129. Miean KH, Mohamed S. Flavonoids (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem. 2001;49:3106-3112.
130. Ding Y, Zhang ZF, Dai XQ, et al. Myricetin protects against cytokine-induced cell death in RIN-m5f beta cells. J Med Food. 2012;15:733-740.
131. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension. 2001;37:1336-1340.
132. Ramanathan T, Skinner H. Coronary blood flow. Contin Educ Anaesth Crit Care Pain. 2005;5:61-64.
133. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098.
134. Chanet A, Milenkovic D, Manach C, et al. Citrus flavanones: what is their role in cardiovascular protection? J Agric Food Chem. 2012;60:8809-8822.
135. Ramprasath T, Senthamizharasi M, Vasudevan V, et al. Naringenin confers protection against oxidative stress through upregulation of Nrf2 target genes in cardio-myoblast cells. J Physiol Biochem. 2014;70-407-415.
136. Toh JY, Tan VM, Lim PC, et al. Flavonoids from fruit and vegetables: a focus on cardiovascular risk factors. Curr Atheroscler Rep. 2013;15:368. doi:10.1007/ s11883-013-0368-y.
137. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta. 1999;1411:273-289.
138. Parhiz H, Roohbakhsh A, Soltani F, et al. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperitin: an updated review of their molecular mechanisms and experimental models. Phytother Res. 2015;29:323-331.
139. Aron PM, Kennedy JA. Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res. 2008;52:79-104.
140. Yao LH, Jiang YM, Shi J, et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr. 2004;59:113-122.
141. Vogiatzoglou A, Heuer T, Mulligan AA, et al. Estimated dietary intakes and sources of flavanols in the German population (German National Nutrition Survey II). Eur J Nutr. 2014;53:635-643.
142. Balasuriya BWN, Rupasinghe HPV. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. Funct Food Health Dis. 2011;5:172-188.
143. Parichatikanond W, Pinthong D, Mangmool S. Blockade of the renin-angiotensin system with delphinidin, cyanin, and quercetin. Planta Medica. 2012;78:1626-1632.
144. Testai L, Martelli A, Cristofaro M, et al. Cardioprotective effects of different flavonoids against myocardial ischaemia/reperfusion injury in Langendorff-perfused rat hearts. J Pharm Pharmacol. 2013;65:750-756.
145. Nguyen MA, Staubach, P, Wolffram S, et al. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci. 2014;61:54-60.
146. Harasstani OA, Moin S, Tham CL, et al. Flavonoid combinations cause synergistic inhibition of proinflammatory mediator secretion from lipopolysaccharide-induced RAW 264.7 cells. Inflamm Res. 2010;59:711-721.
147. Johnson MH, de Mejia EG, Fan J, et al. Anthocyanins and proanthocyanidins from blueberry-blackberry fermented beverages inhibit markers of inflammation in macrophages and carbohydrate-utilizing enzymes in vitro. Mol Nutr Food Res. 2013;57:1182-1197.
148. Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharmaceut Res. 2004;21:1263-1273.
149. Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960-963.
150. Galati G, O'Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radical Biol Med. 2004;37:287-303.
151. Brunetti C, Di Ferdinando M, Fini M, et al. Flavonoids as antioxidants and developmental regulators: relative significance in plants and humans. Int J Mol Sci. 2013;14:3540-3555.